TCL Archive Lilly drug Alimta misses the target, but wins ODAC endorsement for lung cancer. FDA’s Pazdur tells ODAC that decision on Alimta requires clinical judgment. July 30, 2004
TCL Archive NCI Advisors Approve Recompetition Of $132 Million Proteomic Technologies Network March 12, 2010
TCL Archive DCCP Board Gives Concept Approval To RFA For Biochemical Epidemiolgy, New And Recompeting Contract Program September 23, 1983
TCL Archive Guidelines Working Group Agrees On 4750,00 As Base; Steckel Says AACI May Object To “Freeze” On Core November 21, 1980
